In our latest Pα+ interview, Psychedelic Alpha Editor Josh Hardman sits down with Danielle Schlosser, co-founder and Chief Innovation Officer at mpathic, an AI-powered software platform that aims to enhance sponsor oversight of clinical trials, including any psychosocial support element as well as clinical outcome assessments.
mpathic has attracted interest from psychedelic drug developers in particular, with companies like Transcend Therapeutics and atai Life Sciences using the tool. That’s perhaps unsurprising, as such sponsors are often looking to better characterise and standardise the psychosocial support delivered as part of their protocols, whatever they may call it.
In this interview, Schlosser and Hardman discuss the company’s offering and how it might help with thorny issues in psychedelic drug development. They also cover broader topics, like whether large language models might be able to predict which patients will be responders before they’re administered a psychedelic, how study therapists feel about being monitored by an AI, and the potential for measuring the consistency and quality of psychosocial support in a post-approval context.
To read this interview, please sign in to your Pα+ account…
Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and culture.
Already a member? Log In
✓ Regular Bulletins covering key topics and trends in the psychedelics space
✓ Regular articles and deep dives across psychedelic research, policy and business
✓ Interviews with insiders
✓ Monthly interactive database and commentary on psychedelic patents
✓ Quick-take analysis of major developments
✓ A Library of primers and explainers
✓ Access to our full back catalogue